https://www.selleckchem.com/pr....oducts/elexacaftor.h
the treating team should be aware that younger patients and patients without a history of trauma are at a higher risk for having bilateral symptoms. Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence. Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence. The MELFO (MELanoma FOllow-up) study is an international phase III randomized controlled trial comparing an experimental low-intensity schedule against current national guidelines. Evid
Like
Comment
Share
